Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (4)

• Lilly trial drug cuts spleen size, symptoms in myelofibrosis Stock Titan · 1d ago
• AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis OncLive · 1d ago
• Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting investor.lilly.com · 1d ago
• Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ Fierce Biotech · 1d ago

Related trends